医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata NEXT Seoul and Shanghai Events Host Industry Thought Leaders at the Forefront of the Digital Transformation in Life Sciences

2018年07月12日 AM06:58
このエントリーをはてなブックマークに追加


 

SHANGHAI

This week, the Asia Pacific segment of Medidata’s (NASDAQ:MDSO) global NEXT series continues with customer events in Seoul and Shanghai. Sessions will explore trends in virtual trials, mobile healthcare, real-world evidence, artificial intelligence, and machine learning.

The digital transformation of clinical trials is among the many topics being discussed by company executives and hundreds of life science leaders in the region.

NEXT Seoul concluded Tuesday with more than 400 attendees. Keynote speakers included Professor Daeho Lee from Asan Medical Center who discussed the importance of patient centricity in clinical research, and Mr. Sangjoon Lee who outlined how technology revolutionized new drug development for his company, Celltrion.

NEXT Shanghai takes place Thursday, with over 800 attendees expected from leading pharmaceutical companies, including Fosun, and 13 CRO sponsors, including Paraxel, TigerMed, FMD K&L, and Wuxi CDS. Keynote speakers from China Drug Administration (formerly CFDA) and University of Tokyo Hospital in Shanghai will explore the future blueprint of drug development.

“This week is a great opportunity for life science leaders in the region to share insight about the future of drug development,” said Glen de Vries, president and co-founder, Medidata. “I’m excited to join over 1,200 customers and partners as we discuss the digital transformation of our industry.”

Learn more about Medidata NEXT global events and register today for NEXT NYC.

About Medidata

Medidata is leading the digital transformation of life sciences, with the world’s most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users everyday to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005864/en/

CONTACT

Medidata Solutions
Investors:
Betsy Frank, 917-522-4620
bfrank@mdsol.com
or
Media:
Erik
Snider, 646-362-2997
esnider@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法